Ompenaclid (RGX-202) is an oral small molecule inhibitor of SLC6A8 that induces apoptosis (cell death) of colorectal cancer cells.
RGX-104 is an oral small molecule activator of LXR/APOE that inhibits the growth of tumor blood vessels (angiogenesis) and activates tumor myeloid cells to enhance the immune response against tumors.
RGX-019 is a monoclonal antibody-drug conjugate (ADC) that targets MERTK to selectivity kill cancer cells and activate tumor myeloid cells.
We are actively recruiting patients for clinical trials of ompenaclid (RGX-202) and RGX-104.
Science underlying Inspirna’s technology and pipeline has been published in leading scientific journals
Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer
Abequolixron in combination with docetaxel in heavily-pretreated NSCLC and SCLC is well tolerated and demonstrates encouraging preliminary clinical activity January
Inspirna to Present at the Evercore ISI Annual HealthCONx Conference
November 17, 2022 08:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small
Evercore ISI Annual HealthCONx Conference Fireside Chat
Event: Evercore ISI Annual HealthCONx Conference Fireside Chat Time: November 29, 2022 at 4:45pm ET Webcast Link